HSA
ANIK icon

Hussman Strategic Advisors’s Anika Therapeutics ANIK Stock Holding History

Hussman Strategic Advisors’s Portfolio ANIK Stock Details ANIK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-25,000
Closed -$1.35M – 218
2017
Q4 		$1.35M Buy
+25,000
New +$1.38M 0.39% 96

Other funds holding ANIK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Kayne Anderson Rudnick Investment Management
Kayne Anderson Rudnick Investment Management Los Angeles, California $32.2B AUM 10.98% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Stifel Financial
Stifel Financial St. Louis, Missouri $120B AUM 27.84% 1-Year Est. Return
AAM
AMI Asset Management Los Angeles, California $1.74B AUM 26.89% 1-Year Est. Return

Hussman Strategic Advisors's ANIK Position: Q1 2018 in Review

Hussman Strategic Advisors sold out of Anika Therapeutics (ANIK) in Q1 2018, closing a stake of 25,000 shares — an estimated $1.35M sold.

Hussman Strategic Advisors first reported a position in ANIK in Q4 2017 and held it in 1 quarter. The position peaked at $1.35M in Q4 2017. 170 funds tracked by Wall St. Rank hold ANIK as of Q1 2018.

  • Hussman Strategic Advisors reported no remaining Anika Therapeutics position as of Q1 2018 after selling out during the quarter.
  • Hussman Strategic Advisors sold 25,000 Anika Therapeutics shares in Q1 2018, an estimated $1.35M.
  • Hussman Strategic Advisors first reported a position in Anika Therapeutics in Q4 2017 and held it in 1 quarter.
  • Hussman Strategic Advisors's Anika Therapeutics position peaked at $1.35M in Q4 2017.
  • 170 funds tracked by Wall St. Rank held Anika Therapeutics as of Q1 2018.

Based on Hussman Strategic Advisors's 13F filing for Q1 2018, filed 1 May 2018.